Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced significant leadership changes. Eric Benjamin has been promoted to Chief Operating Officer, where he will lead the company's growth and innovation initiatives across new products, markets, and commercial expansion. Additionally, Manoj Raghunandanan joins as Chief Growth Officer, bringing over 20 years of global consumer health leadership experience from Kenvue.
Benjamin, who joined Insulet in 2015, has been crucial in transforming the company through launching products like Omnipod DASH® and Omnipod 5®, expanding into type 2 diabetes markets, and improving customer experience. Raghunandanan will lead Insulet's new Growth organization, focusing on global strategy and commercial capabilities development.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced its participation in three upcoming investor conferences in September 2025:
• Wells Fargo Healthcare Conference in Boston - September 4 at 3:00 p.m. ET
• Baird Global Healthcare Conference in New York City - September 9 at 12:15 p.m. ET
• Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York City - September 24 at 9:40 a.m. ET
The company will provide live audio webcasts of the presentations, which will be available on their investor relations website. Insulet is known for its Omnipod Insulin Management System, including the innovative Omnipod 5 Automated Insulin Delivery System that integrates with continuous glucose monitoring.
Insulet Corporation (NASDAQ: PODD) reported exceptional Q2 2025 financial results, with total revenue reaching $649.1 million, up 32.9% year-over-year. The company's flagship Omnipod product line generated $639.0 million in revenue, showing strong growth in both U.S. (28.7%) and International (45.0%) markets.
Key financial metrics improved significantly, with gross margin expanding to 69.7% and operating income reaching $121.1 million. The company reported net income of $22.5 million, or $0.32 per diluted share.
Following these strong results, Insulet raised its full-year 2025 guidance, now expecting total revenue growth of 24-27% in constant currency and adjusted operating margin of 17.0-17.5%. Strategic highlights included the expansion of Omnipod 5 compatibility with various CGM sensors across different markets.
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its second quarter 2025 financial results on August 7, 2025, before markets open. Management will host a conference call at 8:00 a.m. ET the same day.
The company specializes in the Omnipod Insulin Management System, featuring a unique tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitoring and can be controlled via smartphone in the U.S.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami. The presentation is scheduled for June 10, 2025, at 9:20 a.m. ET. The company will provide a live audio webcast accessible through their investor relations website.
Insulet specializes in the Omnipod Insulin Management System, offering a unique tubeless disposable Pod that provides three days of continuous insulin delivery without needles. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has released its 2024 Sustainability Report highlighting significant ESG achievements. The company met 11% of its global electricity needs with renewable energy and installed over 5,700 solar panels at its Malaysia facility, covering 21% of the facility's electricity needs. The facility is designed to achieve GBI and LEED Silver certifications.
Key accomplishments include collecting 7.4 million Pods through global takeback programs and expanding access to Omnipod 5 internationally through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors. The company also launched the Omnipod 5 App for iPhone and introduced "Insulet for Good," a global corporate giving program that exceeded employee engagement goals.
Insulet (NASDAQ: PODD) has appointed Ashley McEvoy as President and CEO, effective immediately, replacing Jim Hollingshead who will cease employment on April 28, 2025. McEvoy brings nearly three decades of healthcare leadership experience, previously serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech business.
Under Hollingshead's leadership, Insulet launched Omnipod 5, achieving market leadership in type 1 diabetes in the U.S. and Europe, and became first-to-market in Automated Insulin Delivery for type 2 diabetes in the U.S. The company expects to exceed its Q1 2025 revenue guidance and plans to raise full-year 2025 guidance, with details to be announced on May 8, 2025.
Due to the leadership transition, Insulet has postponed its previously scheduled June 5, 2025 Investor Day to a later date.